Evidence map›Paper›PMID 27621403›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016

Reply to F. Tomao et al.

Karin Ribi, Jürg Bernhard, Weixiu Luo, Meredith M Regan, Gini F Fleming, Prudence A Francis

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Karin RibiKarin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.
Jürg BernhardKarin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.
Weixiu LuoKarin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.
Meredith M ReganKarin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.
Gini F FlemingKarin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.
Prudence A FrancisKarin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
SWOG - Foreign Accrual under UMiU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BLANKE, CHARLES D. · 1985 to 2013
$141.3M
ECOG OPERATIONS OFFICE (IBCSG)U10CA021115 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2013
$132.6M
PRIMARY CANCER THERAPY GROUP--NSABP (HEADQUARTERS)U10CA012027 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WOLMARK, NORMAN · 1985 to 2012
$117.2M
NSABP Foreign AccrualsU10CA037377 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WOLMARK, NORMAN · 1985 to 2014
$116.5M
STUDY TO ASSESS RALOXIFENE FOR PREVENTING BREAST CANCERU10CA069974 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COSTANTINO, JOSEPH P. · 1995 to 2013
$62.4M
PRIMARY BREAST CANCER THERAPY--BIOSTATISTICS CENTERU10CA069651 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COSTANTINO, JOSEPH P. · 1995 to 2012
$52.1M
NCIC Foreign AccrualsU10CA077202 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI EISENHAUER, ELIZABETH · 1998 to 2013
$14.6M
IBCSG STATISTICAL CENTER--A BREAST CANCER STUDY RESOURCEU24CA075362 · NCI · DANA-FARBER CANCER INSTITUTE · PI REGAN, MEREDITH M · 1997 to 2015
$7.5M
EASTERN COOPERATIVE ONCOLOGY GROUPU10CA016116 · NCI · JOHNS HOPKINS UNIVERSITY · PI FORASTIERE, ARLENE ANN · 1985 to 2013
$4.0M
NCI NIH HHS N01 CA032102NCI NIH HHS U10 CA012027NCI NIH HHS U10 CA016116NCI NIH HHS U10 CA021115NCI NIH HHS U10 CA032102NCI NIH HHS U10 CA037377NCI NIH HHS U10 CA069651NCI NIH HHS U10 CA069974NCI NIH HHS U10 CA077202NCI NIH HHS U10 CA180821NCI NIH HHS U24 CA075362
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic NeoplasmsHumans

Identifiers

PMID27621403
PMCPMC5477822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.